close
Add to watchlist
Targacept Inc (TRGT) Healthcare
Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of neuronal nicotinic receptor (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system. It markets Inversine, which is for the management of moderately severe to severe hypertension and uncomplicated cases of malignant hypertension. The company's clinical stage product candidates include TC-5214 in Phase 2b clinical trial that modulates the activity of various NNR subtypes, including multiple forms of the a4ß2 NNR; AZD3480 (TC-1734), a small molecule, which modulates the activity of the a4ß2 NNR and completed two Phase 2b clinical trials; and TC-5619, a small molecule for cognitive dysfunction in schizophrenia or conditions characterized by cognitive impairment that completed a Phase 1 single and multiple rising dose clinical trial. It also has clinical stage product candidates, such as TC-2216, a product candidate for depression and anxiety disorders that completed a Phase 1 single rising dose clinical trial; and AZD1446 (TC-6683), a small molecule in Phase 1 clinical development that modulates the activity of the a4ß2 NNR. In addition, the company has preclinical research programs to discover and develop compounds that act on the a4ß2 NNR; and a program focused on the role of NNRs in inflammation. It has a cognition-focused collaboration with AstraZeneca AB. The company has a strategic alliance with SmithKline Beecham Corporation and Glaxo Group Limited to discover, develop, and market product candidates that selectively target specified NNR subtypes in therapeutic focus areas, including pain, smoking cessation, addiction, obesity, and Parkinson's disease. Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 7.46 |
| Volume | 182930 |
| Volume Avg | 562303 |
| 52 Week High | 28.22 |
| 52 Week Low | 4.91 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.27 |
| EPS change Q/Q | -1000% |
| EPS change Q/Q Yr ago | 79.17% |
| EPS change Q/Q next Q est | -1000% |
| EPS change Y/Y | 1000% |
| REV change Q/Q | 65.96% |
| REV change Q/Q Yr ago | 100% |
| EPS next Q est | -0.21 |
| EPS next Y est | -0.11 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |